ArticleThe Journal of clinical investigation2018

Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.

Hui-Ming Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.